Method of manufacturing composite riser
    13.
    发明申请
    Method of manufacturing composite riser 失效
    制造复合提升管的方法

    公开(公告)号:US20060188342A1

    公开(公告)日:2006-08-24

    申请号:US11413449

    申请日:2006-04-28

    CPC classification number: E21B17/01 E21B17/085

    Abstract: A method of manufacturing a composite riser section with a liner assembly comprises holding the liner assembly in a horizontal position, bowing the liner assembly upward, and winding resin impregnated fibers about the liner assembly to form a structural composite overwrap. Another method of manufacturing a composite riser with a liner assembly comprises holding the liner assembly in a horizontal position between two supports, and winding resin impregnated fibers about the liner assembly to form a structural composite overwrap. A system for manufacturing a composite riser section with a liner assembly having a longitudinal axis comprises a first support and a second support that hold the liner assembly in a horizontal position therebetween, and a plurality of rollers that rotate the liner assembly about the longitudinal axis.

    Abstract translation: 一种制造具有衬套组件的复合提升部分的方法包括将衬套组件保持在水平位置,向上弯曲衬套组件,并将树脂浸渍的纤维缠绕在衬套组件上以形成结构复合外包装。 制造具有衬套组件的复合提升管的另一种方法包括将衬套组件保持在两个支撑件之间的水平位置,以及围绕衬套组件卷绕树脂浸渍的纤维以形成结构复合外包装。 用于制造具有纵向轴线的衬套组件的复合提升部分的系统包括第一支撑件和将衬套组件保持在水平位置之间的第二支撑件以及使衬套组件围绕纵向轴线旋转的多个辊子。

    Compositions and methods for targeting a polypeptide to the central nervous system
    14.
    发明申请
    Compositions and methods for targeting a polypeptide to the central nervous system 审中-公开
    将多肽靶向中枢神经系统的组合物和方法

    公开(公告)号:US20050100986A1

    公开(公告)日:2005-05-12

    申请号:US10861779

    申请日:2004-06-04

    Abstract: The invention provides a chimeric CNS targeting polypeptide having a BBB-receptor binding domain and a payload polypeptide domain. The chimeric CNS targeting polypeptide can have a BBB-receptor binding domain consisting of a receptor binding domain from ApoB, ApoE, aprotinin, lipoprotein lipase, PAI-1, pseudomonas exotoxin A, transferrin, α2-macroglobulin, insulin-like growth factor, insulin, or a functional fragment thereof. Nucleic acids encoding a chimeric CNS targeting polypeptide are also provided. Further provided is a method of delivering a polypeptide to the CNS of an individual. The method consists of administering to the individual an effective amount of a chimeric CNS targeting polypeptide, said chimeric CNS targeting polypeptide comprising a BBB-receptor binding domain and a payload polypeptide domain. The method also can deliver a polypeptide to the lysosomes of CNS cells.

    Abstract translation: 本发明提供了具有BBB受体结合结构域和有效载荷多肽结构域的嵌合CNS靶向多肽。 嵌合CNS靶向多肽可以具有由ApoB,ApoE,抑肽酶,脂蛋白脂肪酶,PAI-1,假单胞菌外毒素A,转铁蛋白,α2-巨球蛋白,胰岛素样生长因子,胰岛素的受体结合结构域组成的BBB受体结合结构域 ,或其功能片段。 还提供了编码嵌合CNS靶向多肽的核酸。 还提供了将多肽递送至个体的CNS的方法。 该方法包括向个体施用有效量的嵌合CNS靶向多肽,所述嵌合CNS靶向多肽包含BBB受体结合结构域和有效载荷多肽结构域。 该方法还可以将多肽递送至CNS细胞的溶酶体。

    COMPOUNDS FOR REVERSING AND INHIBITING PROTEIN AGGREGATION, AND METHODS FOR MAKING AND USING THEM
    19.
    发明申请
    COMPOUNDS FOR REVERSING AND INHIBITING PROTEIN AGGREGATION, AND METHODS FOR MAKING AND USING THEM 有权
    用于反转和抑制蛋白质聚集的化合物及其制备和使用它们的方法

    公开(公告)号:US20110223240A1

    公开(公告)日:2011-09-15

    申请号:US13119400

    申请日:2009-09-29

    CPC classification number: C07K14/4711 A61K38/00 C07K19/00

    Abstract: The invention provides compositions for increasing the clearance of protein aggregates, and pharmaceutical compositions comprising them, and methods for making and using them, including methods for accelerating protein aggregate clearance in the CNS, e.g., for treating diseases that are characterized by protein aggregation—including some degenerative neurological diseases such as Parkinson's disease. In one aspect, the compositions of the invention specifically target synuclein, beta-amyloid and/or tau protein aggregates, and the methods of the invention can be used to specifically prevent, reverse, slow or inhibit synuclein, beta-amyloid and/or tau protein aggregation. In alternative embodiments, the compositions and methods of the invention, are used to treat, prevent, reverse (partially or completely) or ameliorate (including slowing the progression of) degenerative neurological diseases related to or caused by protein aggregation, e.g., synuclein, beta-amyloid and/or tau protein aggregation. In one aspect, compositions and methods of this invention are used to treat, prevent or ameliorate (including slowing the progression of) Parkinson's disease, fronto-temporal dementia (FTD), Alzheimer's Disease (AD), Lewy body disease (LBD) and Multiple system atrophy (MSA).

    Abstract translation: 本发明提供了用于增加蛋白质聚集体清除率的组合物,以及包含它们的药物组合物,以及用于制备和使用它们的方法,包括用于加速CNS中的蛋白质聚集体清除的方法,例如用于治疗以蛋白质聚集为特征的疾病 一些退行性神经系统疾病如帕金森病。 在一个方面,本发明的组合物特异性靶向突触核蛋白,β-淀粉样蛋白和/或tau蛋白聚集体,并且本发明的方法可用于特异性地预防,逆转,减缓或抑制突触核蛋白,β-淀粉样蛋白和/或tau 蛋白质聚集。 在替代实施方案中,本发明的组合物和方法用于治疗,预防,逆转(部分或完全)或改善(包括减缓进展)与蛋白质聚集相关或由其引起的退行性神经疾病,例如突触核蛋白,β - 淀粉样蛋白和/或tau蛋白聚集。 一方面,本发明的组合物和方法用于治疗,预防或改善(包括减缓帕金森氏病,颞叶性痴呆(FTD),阿尔茨海默病(AD),路易体病(LBD)和多发性硬化症 系统萎缩(MSA)。

Patent Agency Ranking